F. Hoffmann-La Roche Ltd, Formulation R&D Biologics, Pharmaceutical and Analytical R&D, Basel, Switzerland.
J Pharm Sci. 2009 Dec;98(12):4525-33. doi: 10.1002/jps.21776.
The development of high concentration antibody formulations presents a major challenge for the formulation scientist, as physical characteristics and stability behavior change compared to low concentration protein formulations. The aim of this study was to investigate the potential correlation between surface activity and shaking stress stability of a model antibody-polysorbate 20 formulation. The surface activities of pure antibody and polysorbate 20 were compared, followed by a study on the influence of a model antibody on the apparent critical micelle concentration (CMC) of polysorbate 20 over a protein concentration range from 10 to 150 mg/mL. In a shaking stress experiment, the stability of 10, 75, and 150 mg/mL antibody formulations was investigated containing different concentrations of polysorbate 20, both below and above the CMC. The antibody increased significantly the apparent CMC of antibody-polysorbate 20 mixtures in comparison to the protein-free buffer. However, the concentration of polysorbate required for stabilization of the model antibody in a shaking stress experiment did not show dependence on the CMC. A polysorbate 20 level of 0.005% was found sufficient to stabilize both at low and high antibody concentration against antibody aggregation and precipitation.
高浓度抗体制剂的开发对制剂科学家来说是一个重大挑战,因为与低浓度蛋白质制剂相比,其物理特性和稳定性行为发生了变化。本研究旨在探讨模型抗体-聚山梨酯 20 制剂的表面活性与振摇应激稳定性之间的潜在相关性。比较了纯抗体和聚山梨酯 20 的表面活性,然后研究了模型抗体对聚山梨酯 20 表观临界胶束浓度(CMC)的影响,研究范围为 10 至 150mg/mL 的蛋白质浓度。在振摇应激实验中,研究了浓度分别为 10、75 和 150mg/mL 的抗体制剂在 CMC 以下和以上时的稳定性,其中含有不同浓度的聚山梨酯 20。与不含蛋白质的缓冲液相比,抗体显著增加了抗体-聚山梨酯 20 混合物的表观 CMC。然而,在振摇应激实验中稳定模型抗体所需的聚山梨酯 20 浓度并不依赖于 CMC。发现 0.005%的聚山梨酯 20 水平足以稳定低浓度和高浓度抗体,防止抗体聚集和沉淀。